Unmet needs in the treatment of autoimmunity: From aspirin to stem cells

Chang, Christopher

doi:10.1016/j.autrev.2014.01.052

Cited by 22 publications

(16 citation statements)

References 247 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NSAIDs have no effect on disease progression but control stiffness, pain and inflammation . Introducing glucocorticoids and biological response modifier drugs, especially the anti‐TNF agents have provided better and more efficacious drugs to decrease joint pain and swelling with lesser side effects . Activation of TNF‐α is through the TNF‐α associated factor 1 ( TRAF1 ) and TRAF2 receptors and is mediated through activation of NF‐kB, the MAP kinase pathway and death signaling .…”

Section: Therapeutic Strategies and Treatment For Ramentioning

confidence: 99%

The genetic pathogenesis, diagnosis and therapeutic insight of rheumatoid arthritis

Zamanpoor

2019

Clinical Genetics

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a systemic autoimmune disease that causes chronic inflammation of the joints. RA is a heterogeneous disorder caused by an abnormal autoimmune response triggered by the complex interactions of genetic and environmental factors that contribute to RA etiology. However, its underlying pathogenic mechanisms are yet to be fully understood. In this review, I provide an overview of the pathogenesis, diagnosis and therapeutic insight in the clinical management of RA in light of the recent updates to classification criteria and recent discoveries of genetic loci associated with susceptibility for RA.

show abstract

Section: Therapeutic Strategies and Treatment For Ramentioning

confidence: 99%

The genetic pathogenesis, diagnosis and therapeutic insight of rheumatoid arthritis

Zamanpoor

2019

Clinical Genetics

View full text Add to dashboard Cite

show abstract

“…The adequate strategy for the primary prophylaxis of thrombosis in patients with antiphospholipid antibodies (aPL) remains very controversial [1][2][3][4]. However, experts at the 13th International Congress on antiphospholipid antibodies have advocated the use of low-dose aspirin for primary prophylaxis of thrombosis in aPL carriers with high risk profiles such as lupus anticoagulant (LA) positivity or triple positivity (positivity of LA, anticardiolipin [aCL] and of anti-β2-glycoprotein-I [β2GPI] antibodies) or isolated persistently positive anticardiolipin antibodies aCL at medium-high titers [5].…”

Section: Introductionmentioning

confidence: 99%

Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies

Arnaud

Mathian

Devilliers³

et al. 2015

Autoimmunity Reviews

134

View full text Add to dashboard Cite

“…With the increasing prevalence of autoimmunity in the Western countries (1), the societal burden of these diseases also increases. Although the treatment of autoimmune diseases has improved due to the development of so-called biologics, like tumor necrosis factor alpha (TNFα) inhibitors, a large proportion of patients are still not adequately responding to these treatments (2). Therefore, it is still important to improve current therapies or to uncover new treatment options.…”

Section: Introductionmentioning

confidence: 99%

Vitamin D in Autoimmunity: Molecular Mechanisms and Therapeutic Potential

et al. 2017

View full text Add to dashboard Cite

Over the last three decades, it has become clear that the role of vitamin D goes beyond the regulation of calcium homeostasis and bone health. An important extraskeletal effect of vitamin D is the modulation of the immune system. In the context of autoimmune diseases, this is illustrated by correlations of vitamin D status and genetic polymorphisms in the vitamin D receptor with the incidence and severity of the disease. These correlations warrant investigation into the potential use of vitamin D in the treatment of patients with autoimmune diseases. In recent years, several clinical trials have been performed to investigate the therapeutic value of vitamin D in multiple sclerosis, rheumatoid arthritis, Crohn’s disease, type I diabetes, and systemic lupus erythematosus. Additionally, a second angle of investigation has focused on unraveling the molecular pathways used by vitamin D in order to find new potential therapeutic targets. This review will not only provide an overview of the clinical trials that have been performed but also discuss the current knowledge about the molecular mechanisms underlying the immunomodulatory effects of vitamin D and how these advances can be used in the treatment of autoimmune diseases.

show abstract

Unmet needs in the treatment of autoimmunity: From aspirin to stem cells

Cited by 22 publications

References 247 publications

The genetic pathogenesis, diagnosis and therapeutic insight of rheumatoid arthritis

The genetic pathogenesis, diagnosis and therapeutic insight of rheumatoid arthritis

Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies

Vitamin D in Autoimmunity: Molecular Mechanisms and Therapeutic Potential

Contact Info

Product

Resources

About